BeiGene Ltd. Sponsored ADR Stock

$197.28

0.12% yesterday

Nasdaq, Sep 18, 10:00 pm CET

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

BeiGene Ltd. Sponsored ADR Stock price

$197.28

+66.38 50.71% 5Y

Nasdaq, Closing price Wed, Sep 18 2024

-0.23 0.12%

ISIN

US07725L1026

Symbol

BGNE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$19.18b
Enterprise Value	$17.65b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	5.70
P/S ratio (TTM) P/S ratio	6.19
P/B ratio (TTM) P/B ratio	6.22
Revenue growth (TTM) Revenue growth	71.01%
Revenue (TTM) Revenue	$3.10b
EBIT (operating result TTM) EBIT	$-886.27m
Free Cash Flow (TTM) Free Cash Flow	$-1.29b
Cash position	$2.62b
EPS (TTM) EPS	$-5.08
P/E forward	negative
P/S forward	5.32
EV/Sales forward	4.89
Short interest	4.35%

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Get Started for Free Today

BeiGene Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

30 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

28x Buy

93%

More details on Analyst Estimates Including Price Targets

30 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from BeiGene Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '23		+/- %
Net Profit	-882 -882	56% 56% -36%
Depreciation and Amortization	88 88	32% 32% 4%
Stock Compensation	368 368	21% 21% 15%
Operating Cash Flow	-1,157 -1,157	23% 23% -47%
Investments	581 581	79% 79% 24%
Dividend Paid	- -	- -
Free Cash Flow	-1,719 -1,719	6% 6% -70%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BeiGene Ltd. Sponsored ADR Stock News

Neutral

Business Wire

●

one day ago

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

HERZLIYA, Israel--(BUSINESS WIRE)--Tevimbra has been approved in Israel.

Neutral

Business Wire

●

10 days ago

Phonak + Advanced Bionics sponsor new family film, Rally Caps - Worldwide release on September 10th

STÄFA, Switzerland & VALENCIA, Calif.--(BUSINESS WIRE)-- #cochlear--Phonak, a leading provider of life-changing hearing solutions, and its sister brand and partner Advanced Bionics (AB), a global leader in cochlear implant technology, proudly sponsor Rally Caps. This heartwarming family film highlights the power of team building, friendship, and breaking down stigmas associated with hearing los...

Neutral

Business Wire

●

10 days ago

BeiGene Announces Updates to Commercial Leadership Team

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. “We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franc...

More BeiGene Ltd. Sponsored ADR News

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

Head office	Cayman Islands
CEO	John Oyler
Employees	10,000
Founded	2010
Website	www.beigene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now